2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
2
Stomach Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Oligometastatic Prostate Cancer
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Bile Duct Neoplasms
1
Advanced Non-Small Cell Lung Cancer
1
Adenocarcinoma Of Esophagus
1
Interventions
Docetaxel
6
Gemcitabine
3
Carboplatin
3
lorlatinib
2
cemiplimab
2
Vinorelbine
2
S 1 (combination)
2
Pemetrexed
2
Erlotinib Hydrochloride
2
Cisplatin
2
Cetuximab
2
zimberelimab
1
surufatinib
1
sintilimab
1
quemliclustat
1
pemigatinib
1
pembrolizumab
1
nimotuzumab
1
fludarabine
1
WW Domain-Containing Oxidoreductase
1
Paclitaxel
1
Interleukin-2
1
Gene Expression Profiling
1
Drug Therapy
1
Cyclophosphamide
1
Capecitabine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Non-Small Cell Lung Cancer
×
quemliclustat
×
Clear all
NCT05676931
2026-06-01
EDGE-Lung
Gilead Sciences
Phase 2
Active not recruiting
400 enrolled